<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436107</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-110</org_study_id>
    <nct_id>NCT04436107</nct_id>
  </id_info>
  <brief_title>Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the maximum tolerated doses (MTD) and the
      recommended Phase 2 dose (RP2D), and safety and tolerability of zanubrutinib in combination
      with lenalidomide, with or without rituximab in participants with R/R DLBCL by dose
      escalating lenalidomide
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants Experiencing Severe Adverse Events (SAEs)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Response Rate (ORR)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The proportion of participants who achieve either a partial response (PR) or complete response (CR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Overall Response Rate (ORR)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The proportion of participants who achieve either a partial response (PR) or complete response (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Zero to Last Measurable Concentration (AUC0-t)</measure>
    <time_frame>Cycle 1 Day 1 (C1D1) and C1D21 up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>C1D1 and C1D21 up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>C1D1 and C1D21 up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>C1D1 and C1D21 up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor Occupancy (Ro)</measure>
    <time_frame>C1D1 and C1D21 up to 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Relapsed/Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1 : Zanubrutinib + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanubrutinib for up to 48 months
Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Zanubrutinib+Rituximab+Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanubrutinib for up to 48 months
Rituximab on Day 1 of each 28-day cycle for 6 cycles
Lenalidomide administered orally once daily (QD) at 4 dose levels of escalating doses on Days 1 - 21 of each 28-Day cycle for up to 48 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : Zanubrutinib+Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanubrutinib for up to 48 months
Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>160 mg administered orally twice daily (BID)</description>
    <arm_group_label>Part 1 : Zanubrutinib + Lenalidomide</arm_group_label>
    <arm_group_label>Part 1: Zanubrutinib+Rituximab+Lenalidomide</arm_group_label>
    <arm_group_label>Part 2 : Zanubrutinib+Lenalidomide</arm_group_label>
    <other_name>BGB-3111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Part 1 : Zanubrutinib + Lenalidomide</arm_group_label>
    <arm_group_label>Part 1: Zanubrutinib+Rituximab+Lenalidomide</arm_group_label>
    <arm_group_label>Part 2 : Zanubrutinib+Lenalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered via intravenous (IV) infusion over 30 minutes</description>
    <arm_group_label>Part 1: Zanubrutinib+Rituximab+Lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Histologically confirmed DLBCL, all participants must provide sufficient archival or
             fresh tumor tissue samples for evaluation by immunohistochemistry (IHC) and Gene
             Expression Profiling (GEP).

          2. Relapsed or refractory disease, defined as either: 1) recurrence of disease after a
             complete response (CR), or 2) partial response (PR), stable disease (SD), or
             progressive disease (PD) at completion of the treatment regimen preceding entry to the
             study.

          3. Participants who have not received high dose therapy/stem cell transplantation
             (HDT/SCT) must be ineligible for HDT/SCT.

          4. Measurable disease as defined by at least 1 lymph node &gt;1.5 cm in longest diameter and
             measurable in 2 perpendicular dimensions.

          5. Received an appropriate first-line therapy for DLBCL, that includes anthracycline
             based chemotherapy.

        Key Exclusion Criteria:

          1. Current or history of central nervous system (CNS) lymphoma.

          2. Histologically transformed lymphoma.

          3. History of allogeneic stem-cell transplantation.

          4. Prior exposure to a BTK inhibitor.

          5. Prior exposure to lenalidomide.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aihua Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

